Buprenorphine/naloxone sublingual spray - INSYS Therapeutics

Drug Profile

Buprenorphine/naloxone sublingual spray - INSYS Therapeutics

Alternative Names: Naloxone/buprenorphine sublingual spray - INSYS Therapeutics

Latest Information Update: 18 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator INSYS Therapeutics, Inc
  • Class Antidotes; Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Opioid abuse

Most Recent Events

  • 17 Oct 2016 Phase-II clinical trials in Opioid abuse in USA (Sublingual) (Insys Therapeutics pipeline, October 2016)
  • 01 Jun 2015 INSYS Therapeutics initiates a phase I trial (In volunteers) in USA (NCT02477267)
  • 12 Jan 2015 Phase-I clinical trials in Opioid abuse in USA before January 2015 (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top